Hereditary Cancer Syndromes > BRIP1, BARD1, RAD51C, RAD51D
CANCER
GENETIC CANCER RISK
Female Breast
High Risk
CANCER
GENETIC CANCER RISK
Ovarian
High Risk
CANCER
GENETIC CANCER RISK
Ovarian
High Risk
Breast
High Risk
CANCER TYPE
AGE RANGE
CANCER RISK
RISK FOR GENERAL POPULATION
Female Breast
To age 80
22%, with a particularly increased risk for triple negative breast cancer (TNBC)
10.7%
CANCER TYPE
AGE RANGE
CANCER RISK
RISK FOR GENERAL POPULATION
Ovarian
To age 80
5.8%
0.9%
CANCER TYPE
AGE RANGE
CANCER RISK
RISK FOR GENERAL POPULATION
Ovarian
To age 50
1.0%
0.2%
To age 80
6.7%
0.9%
Female Breast
To age 80
20%, with a particularly increased risk for triple negative breast cancer (TNBC).
10.7%
CANCER TYPE
AGE RANGE
CANCER RISK
RISK FOR GENERAL POPULATION
Ovarian
To age 50
2.3%
0.2%
To age 80
14.8%
0.9%
Female Breast
To age 80
19%, with a particularly increased risk for triple negative breast cancer (TNBC).
10.7%
CANCER TYPE
PROCEDURE
AGE TO BEGIN
FREQUENCY
Female Breast
Breast awareness - Women should be familiar with their breasts and promptly report changes to their healthcare provider. Periodic, consistent breast self-examination (BSE) may facilitate breast awareness.
Individualized
N/A
Clinical encounter, including clinical breast exam, ongoing risk assessment and risk-reduction counseling
When genetic risk is identified, but not before age 21
Every 6 to 12 months
Mammography and consideration of breast MRI with contrast
Age 40, or modified to a younger age based on the family history of breast cancer
Annually
Consider additional risk-reduction strategies.
Individualized
N/A
For Patients With A Cancer Diagnosis
For patients with a gene mutation and a diagnosis of cancer, targeted therapies may be available as a treatment option for certain tumor types (e.g., PARP-inhibitors).
N/A
N/A
CANCER TYPE
PROCEDURE
AGE TO BEGIN
FREQUENCY
Ovarian
Bilateral salpingo-oophorectomy (BSO).
45 to 50 years, or earlier if there is a family history of ovarian cancer at a younger age
N/A
Other than consideration of BSO, currently there are no specific medical management recommendations for ovarian cancer risk in mutation carriers. However, the increase in risk may warrant consideration of individualized ovarian cancer risk-reduction strategies using other currently available options, such as surveillance and the use of risk-reducing agents.
Individualized
N/A
For Patients With A Cancer Diagnosis
For patients with a gene mutation and a diagnosis of cancer, targeted therapies may be available as a treatment option for certain tumor types (e.g., PARP-inhibitors).
N/A
N/A
CANCER TYPE
PROCEDURE
AGE TO BEGIN
FREQUENCY
Ovarian
Bilateral salpingo-oophorectomy (BSO).
45 to 50 years, or earlier if there is a family history of ovarian cancer at a younger age
N/A
Other than consideration of BSO, currently there are no specific medical management recommendations for ovarian cancer risk in mutation carriers. However, the increase in risk may warrant consideration of individualized ovarian cancer risk-reduction strategies using other currently available options, such as surveillance and the use of risk-reducing agents.
Individualized
N/A
Female Breast
Mammography and consideration of breast MRI with contrast
40 years
Annually
For Patients With A Cancer Diagnosis
For patients with a gene mutation and a diagnosis of cancer, targeted therapies may be available as a treatment option for certain tumor types (e.g., PARP-inhibitors).
N/A
N/A
CANCER TYPE
PROCEDURE
AGE TO BEGIN
FREQUENCY
Ovarian
Bilateral salpingo-oophorectomy (BSO).
45 to 50 years, or earlier if there is a family history of ovarian cancer at a younger age
N/A
Other than consideration of BSO, currently there are no specific medical management recommendations for ovarian cancer risk in mutation carriers. However, the increase in risk may warrant consideration of individualized ovarian cancer risk-reduction strategies using other currently available options, such as surveillance and the use of risk-reducing agents.
Individualized
N/A
Female Breast
Mammography and consideration of breast MRI with contrast
40 years
Annually
For Patients With A Cancer Diagnosis
For patients with a gene mutation and a diagnosis of cancer, targeted therapies may be available as a treatment option for certain tumor types (e.g., PARP-inhibitors).
N/A
N/A
